Katalóg evidencie publikačnej činnosti PU

ID záznamu:	PU.Prešov.2022021010563494
Kategória:	ADC
Autor:	Baragetti A. (35%)
Autor:	Grejtáková Daniela (30%)
Autor:	Casula M. (10%)
Autor:	Olmastroni E. (5%)
Autor:	Jotti G.S. (5%)
Autor:	Norata G.D. (5%)
Autor:	Catapano A.L. (5%)
Autor:	Bellosta S. (5%)
Názov:	Proprotein convertase subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps
Zdroj:	Pharmacological research
Lokácia:	No. 130 (2018), s. [1-11]
ISSN:	1043-6618
Ohlas:	[1] 2020. PACKARD, C.J., BOREN, J., TASKINEN, M.R. Causes and consequences of hypertriglyceridemia. In Frontiers in endocrinology, ISSN 1664-2392. 2020, vol. 11, art. no. 252. WOS:000537844300001.
Ohlas:	[1] 2020. CATAPANO, A.L., PIRILLO, A., NORATA, G.D. New pharmacological approaches to target PCSK9. In Current atherosclerosis reports, ISSN 1523-3804. 2020, vol. 22, no. 7, s. [1]. WOS:000540450000001.
Ohlas:	[1] 2019. DEL PINTO, R., GRASSI, D., PROPERZI, G. et al. Low density lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: Potential role of PCSK9 inhibitors. In High blood pressure and cardiovascular prevention, ISSN 1120-9879. 2019, vol. 26, no. 3, s. 199-207.
Ohlas:	[1] 2020. BUSUIOC, R.M., COVIC, A., KANBAY, M. et al. Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. In Nephrology dialysis transplantation, ISSN 0931-0509. 2020, vol. 35, no. 10, s. 1663-1674. WOS:000607839600006.
Ohlas:	[1] 2020. WU, D.Y., ZHOU, Y.Z., PAN, Y.J. et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid beta-oxidation. In Journal of the American heart association, ISSN 2047-9980. 2020, vol. 9, no. 1, s. [1]. WOS:000517998200001.
Ohlas:	[1] 2020. MALVANDI, A.M., CANCLINI, L., ALLIAJ, A. et al. Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. In Expert opinion on biological therapy, ISSN 1471-2598. 2020, vol. 20, no. 12, s. 1477-1489. WOS:000555625500001.
Ohlas:	[1] 2021. HU, D., MAO, L., TANG, X.Y. et al. Nuclear magnetic resonance reveals postprandial low-density lipoprotein cholesterol determined by enzymatic method could be a misleading indicator. In Clinica Chimica Acta, ISSN 0009-8981. 2021, no. 514, s. 59-65. WOS:000612087200010.
Ohlas:	[1] 2021. DONG, Y., MENG, F., WANG, Z. et al. Construction and application of a human scFv phage display library based on Cre-LoxP recombination for anti-PCSK9 antibody selection. In International journal of molecular medicine, ISSN 1107-3756. 2021, vol. 47, no. 2, s. 708-718. WOS:000609879800026.
Ohlas:	[1] 2018. BHATNAGAR, D., SHIRAZ, A. Modulation of cardiovascular risk factors. In Current opinion in lipidology, ISSN 0957-9672. 2018, vol. 29, no. 3, s. 269-270. WOS:000431511600013.
Ohlas:	[1] 2021. SHI, J., LI, X., ZHANG, W. et al. Circulating proprotein convertase subtilisin/Kexin type 9 levels and cardiometabolic risk factors: A population-based cohort study. In Frontiers in cardiovascular medicine, ISSN 2297-055X. 2021, vol. 8, art. no. 664583, art. no. 664583. WOS:000652969500001.
Ohlas:	[1] 2018. THEOCHARIDOU, E., PAPADEMETRIOU, M., REKLOU, A. et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. In Current pharmaceutical design, ISSN 1381-6128. 2018, vol. 24, no. 31, s. 3654-3657. WOS:000454705800009.
Ohlas:	[3] 2021. VONG, Ch., FONG CHU, M., CHIO TAM, W. et al. Use of alirocumab for the secondary prevention of cardiovascular disease in a patient with end-stage renal disease on hemodialysis. In Malaysian journal of pharmacy, ISSN 1675-366. 2021, vol. 7, no. 2, s. 76.
Ohlas:	[3] 2018. CICCARELLI, G., D`ELIA, S., DE PAULIS, M. et al. Lipid target in very high-risk cardiovascular patients: lesson from PCSK9 monoclonal antibodies. In Diseases, ISSN 2079-9721. 2018 [cit. 2022-02-14], vol. 6, no. 1, s. [1-16]. Dostupný na internete <https://www.mdpi.com/2079-9721/6/1/22/htm>
Ohlas:	[1] 2018. RUSCICA, M., FERRI, N., MACCHI, C. et al. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. In Annals of medicine, ISSN 0785-3890. 2018, vol. 50, no. 6, s. 461-484. WOS:000458287100002.
Ohlas:	[1] 2020. WARDEN, B.A., FAZIO, S., SHAPIRO, M.D. The PCSK9 revolution: Current status, controversies, and future directions. In Trends in cardiovascular medicine, ISSN 1050-1738. 2020, vol. 30, no. 3, s. 179-185. WOS:000520948400014.
Ohlas:	[3] 2021. MCMAHON, M., SETO, R., SKAGGS, B.J. Cardiovascular disease in systemic lupus erythematosus. In Rheumatology and immunology [online], ISSN 2719-4523. 2021 [cit. 2022-03-21], vol. 2, no. 3, s. 167. Dostupný na internete <https://www.degruyter.com/document/doi/10.2478/rir-2021-0022/html>
Ohlas:	[3] 2021. CHAULIN, A.M., DUPLYAKOV, D.V. On the role of PCSK9 in the development of atherosclerosis: molecular aspects. In Molekuľarnaja medicina, ISSN 1728-2918. 2021, roč. 19, č. 2, s. [3].
Ohlas:	[1] 2023. KHALIFEH, M., SANTOS, R.D., OSKUEE, R.K. et al. A novel regulatory facet for hypertriglyceridemia: The role of microRNAs in the regulation of triglyceride-rich lipoprotein biosynthesis. In Progress in lipid research, ISSN 0163-7827. 2023, roč. 90, art. no. 101221. WOS:000896741600002; SCOPUS.
Ohlas:	[1] 2022. SUN, H.M., MENG, W., ZHU, J. et al. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. In Naunyn - Schmiedeberg's archives of pharmacology, ISSN 0028-1298. 2022, roč. 395, č. 6, s. 643-658. WOS:000770953500001; SCOPUS.
Ohlas:	[1] 2022. AYOUB, C., AZAR, Y., MADDAH, D. et al. Low circulating PCSK9 levels in LPL homozygous children with chylomicronemia syndrome in a syrian refugee family in Lebanon. In Frontiers in genetics, ISSN 1664-8021. 2022, roč. 13, art. no. 961028. WOS:000849777900001; SCOPUS.
Ohlas:	[1] 2022. PENG, J., LIU, M.M., JIN, J.L. et al. NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. In Lipids in health and disease, ISSN 1476-511X. 2022, roč. 21, č. 1, art. no. 3. WOS:000740255400005; SCOPUS.
Oblasť výskumu:	120
Oblasť výskumu:	130